CHMP Recommends Subcutaneous RYBREVANT▼ (amivantamab) for the Treatment of Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
February 05, 2025
February 05, 2025
NEW BRUNSWICK, New Jersey, Feb. 5 -- Johnson and Johnson issued the following news release:
* * *
CHMP recommends subcutaneous RYBREVANT▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related reactions and fewer veno . . .
* * *
CHMP recommends subcutaneous RYBREVANT▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related reactions and fewer veno . . .